Voluntary nationwide recall: Sodium Bicarb and Atropine (Hospira – December)
Jan. 2024Pharmacy Updates
Hospira Inc. is recalling several lots of 4.2% Sodium Bicarbonate Injection, USP, 8.4% Sodium Bicarbonate Injection, USP, and Atropine Sulfate Injection, USP. Sodium Bicarbonate is used for the treatment of metabolic acidosis (a buildup of acid in the body). Atropine Sulfate is used for temporary blockade of severe or life-threatening muscarinic effects (effects on certain nerves of the body).
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Sedgwick Inc. at 1-800-805-3093. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
CME Webinar Series: Introducing Physicians and their teams to Value-Based Health Care
Please join us for a new CME-accredited webinar series on value-based care. This series is designed to introduce practicing physicians and their teams to value-based health care. Over the course of six sessions, we will define the components of value and identify the tools necessary to deliver high-value care for a population.Feb. 2026Education/Webinars
Bridging Smiles and Systems: Collaborative Care for Children with Chronic Conditions
Please join us for a live, CME-accredited and CEU-accredited webinar on May 13 from noon to 1p.m., that will explore the critical connection between oral health and pediatric chronic conditions such as diabetes, asthma, congenital heart disease, and ADHD.Feb. 2026Education/Webinars
February 2026 UPMC for You and UPMC Community HealthChoices formulary update
Pulmicort Flexhaler has a new distributor, Rubicon Holding. National Drug Codes (NDCs) for Pulmicort Flexhaler from Rubicon Holding are not included in the Medicaid Drug Rebate program and are not covered under the Medicaid Prescription Drug Program. Pulmicort Flexhaler NDCs from the previous manufacturer, H2 Pharma, have been discontinued but may be billed/dispensed until supplies are exhausted.Feb. 2026Pharmacy Updates